Vista Pharmaceuticals quarterly results and financials

Vista Pharmaceuticals (BSE 524711)₹6.69+4.69%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Vista Pharmaceuticals reported sales of ₹0 Cr, down 100.0% from Mar 2025, and net profit of −₹5.87 Cr. For the year to Mar 2026, sales were ₹4.99 Cr and net profit −₹12.03 Cr.

Sales (Mar 2026): ₹0 Cr
Net profit (Mar 2026): −₹5.87 Cr
Sales (FY Mar 2026): ₹4.99 Cr
Net profit (FY Mar 2026): −₹12.03 Cr
EPS (Mar 2026): ₹−0.96
Borrowings (Mar 2026): ₹10.01 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Vista Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Vista Pharmaceuticals Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	1.97	3.46	1.69	3.12	1.79	2.48	2.55	3.22	1.51	1.45	2.41	0.00
Expenses	2.91	4.65	3.45	2.88	2.59	3.33	4.09	4.15	2.64	4.90	5.43	7.07
Operating Profit	−0.93	−1.18	−1.75	0.27	−0.79	−0.84	−1.53	−0.92	−1.12	−3.44	−3.01	−7.07
OPM %	−46.5%	−33.7%	−102.4%	8.3%	−43.4%	−33.4%	−59.4%	−28.2%	−73.1%	−234.9%	−124.0%	—
Other Income	0.12	0.09	0.01	0.11	0.06	0.00	0.11	0.25	0.00	0.18	0.10	0.02
Interest	0.34	0.33	0.31	0.29	0.29	0.26	0.23	0.22	0.20	0.19	0.19	0.56
Depreciation	0.16	0.17	0.17	0.17	0.17	0.17	0.18	0.17	0.17	0.19	0.18	0.18
Profit before tax	−1.30	−1.60	−2.21	−0.11	−1.18	−1.26	−1.82	−1.07	−1.49	−3.63	−3.29	−7.79
Tax %	−25.6%	27.1%	−25.9%	−190.0%	−26.5%	−22.4%	−26.5%	40.6%	−12.8%	−28.4%	−29.3%	−24.6%
Net Profit	−0.96	−2.03	−1.64	0.10	−0.87	−0.98	−1.33	−1.51	−1.30	−2.60	−2.33	−5.87
EPS (Rs)	−0.27	−0.56	−0.45	0.03	−0.24	−0.27	−0.37	−0.42	−0.22	−0.43	−0.39	−0.96

Vista Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Vista Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	14.96	23.92	28.91	30.89	22.94	0.99	0.00	0.99	9.97	9.98	4.99	5.37
Expenses	13.02	21.03	24.06	30.06	28.06	3.01	2.01	5.01	13.02	14.02	20.04	20.04
Operating Profit	3.01	3.01	5.01	1.01	−5.01	−2.01	−1.01	−4.01	−3.01	−4.01	−15.02	−14.64
OPM %	16.9%	13.0%	17.9%	4.0%	−21.0%	−136.0%	−326.0%	−432.1%	−33.1%	−41.0%	−271.1%	−272.6%
Other Income	0.00	0.00	0.00	2.99	3.99	0.00	0.00	0.00	0.00	0.00	0.00	0.30
Interest	1.01	1.01	2.01	2.01	2.01	2.01	1.01	1.01	1.01	1.01	1.01	1.14
Depreciation	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.72
Profit before tax	1.01	1.01	3.01	1.01	−4.01	−4.01	−3.01	−6.01	−5.02	−5.01	−16.05	−16.20
Tax %	8.0%	−2.0%	23.0%	18.1%	−7.0%	−47.0%	−66.0%	−4.0%	−13.0%	−12.0%	−25.0%	—
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	1.01	1.01	2.01	1.01	−4.01	−2.01	−1.01	−6.01	−5.01	−5.01	−12.03	−12.10
EPS (Rs)	0.07	0.48	0.76	0.32	−1.22	−0.56	−0.25	−1.55	−1.24	−1.27	−1.97	−2.00
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Vista Pharmaceuticals balance sheet

₹ crore, at each year end.

Vista Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4.98	4.98	4.98	5.97	5.98	5.98	6.97	6.97	7.97	8.96	11.95	11.96
Reserves	5.02	6.01	11.02	26.05	30.01	24.01	25.05	28.04	29.04	31.04	33.02	24.05
Borrowings	4.01	8.01	11.02	11.01	11.01	15.00	11.01	13.02	10.01	8.01	7.00	10.01
Other Liabilities	7.97	6.96	13.93	9.95	5.97	5.97	8.95	7.96	8.95	9.96	6.97	8.95
Total Liabilities	22.98	25.96	41.95	52.98	52.97	50.96	52.98	55.99	55.97	57.97	59.94	54.97
Fixed Assets	10.99	9.99	12.99	18.01	20.99	20.98	19.99	18.99	19.98	18.99	18.98	17.99
CWIP	0.00	0.00	2.01	7.01	9.01	9.01	9.01	9.01	9.01	10.01	10.01	11.02
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	11.99	15.97	25.95	27.96	23.97	21.97	23.98	26.99	26.98	28.97	30.95	25.96
Inventories	0.21	2.67	8.13	10.90	11.23	9.67	9.67	9.32	7.67	6.78	8.20	11.00
Trade receivables	11.26	9.71	8.98	10.82	8.33	10.24	2.16	10.42	11.21	14.23	13.49	0.31
Cash & equivalents	0.09	0.42	5.78	1.78	0.86	0.22	0.15	0.06	0.21	0.08	0.74	0.10
Total Assets	22.98	25.96	41.95	52.98	52.97	50.96	52.98	55.99	55.97	57.97	59.94	54.97

Vista Pharmaceuticals cash flow

₹ crore, for each year.

Vista Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	−4.01	−2.01	2.99	−4.99	3.01	1.01	−7.01	−1.01	−2.01	−5.01	−7.01	−4.01
Cash from investing activity	0.00	0.00	−4.01	−11.01	−6.01	−2.01	0.00	0.00	−1.01	−1.01	0.00	−1.01
Cash from financing activity	4.01	3.01	6.01	11.01	1.01	0.00	7.01	1.01	3.01	6.01	8.01	5.01
Net cash flow	0.00	0.00	4.99	−3.99	−0.99	−0.99	0.00	0.00	0.00	0.00	0.99	−0.99
Capex	0.09	0.24	3.63	10.65	5.64	1.72	0.29	0.00	1.28	0.78	0.43	0.77
Free cash flow	−3.99	−3.01	−1.01	−15.01	−2.01	−1.01	−7.01	−1.01	−2.99	−6.01	−6.99	−4.99
CFO / OP %	−131.0%	−89.1%	83.9%	−86.0%	299.0%	−17.1%	390.0%	77.9%	63.9%	148.9%	163.0%	29.9%

Vista Pharmaceuticals ratios

Working-capital days and returns, by year.

Vista Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	300	231	136	137	98	165	624	9,789	4,106	515	505	22
Inventory days	10	97	185	250	162	148	4,840	9,204	991	279	359	770
Days payable	358	235	292	208	75	78	2,554	5,296	1,006	303	243	442
Cash conversion cycle	−51	91	26	177	183	233	2,908	13,695	4,088	489	619	348
Working capital days	−9	205	11	136	136	80	1,680	10,153	3,459	317	439	−96
ROCE %	13.9%	9.9%	9.0%	12.0%	6.0%	−5.0%	−5.0%	−4.0%	−10.0%	−8.0%	−9.0%	−30.0%

Vista Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Vista Pharmaceuticals?

For the Mar 2026 quarter, Vista Pharmaceuticals reported sales of ₹0 Cr, down 100.0% year on year and net profit of −₹5.87 Cr.

What is the annual revenue of Vista Pharmaceuticals?

Vista Pharmaceuticals' sales for the year to Mar 2026 were ₹4.99 Cr; over the last twelve months they were ₹5.37 Cr.

What is the net profit of Vista Pharmaceuticals?

Net profit for the year to Mar 2026 was −₹12.03 Cr, and −₹12.10 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−2.00.

How much debt does Vista Pharmaceuticals have?

Vista Pharmaceuticals reported borrowings of ₹10.01 Cr at Mar 2026, against cash and equivalents of ₹0.10 Cr.

What is the free cash flow of Vista Pharmaceuticals?

Cash from operations was −₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹4.99 Cr.

Loading…